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looks as if it may have to be abandoned 
because Scherrer et al. show that DOR 
is not expressed in substance P-con-
taining neurons. In addition, it looks 
like it behaves as a prototypic GPCR 
with membrane expression in basal 
conditions and internalization on acti-
vation, rather than the use-dependent 
insertion into the membrane suggested 
in current models.
What has so muddied the waters? It 
turns out that perhaps all commercially 
available antibodies raised against 
DOR peptides recognize a protein that 
is still present in mice lacking DOR 
and all immunohistochemistry using 
these antibodies is therefore suspect. 
Scherrer et al. use a DOR-enhanced 
green fluorescent protein (EGFP) 
reporter mouse to show that the recep-
tor is localized in the set of presump-
tive nociceptor neurons that do not 
express substance P. The often made 
jest that the most valuable contribution 
of knockouts is to test antibody speci-
ficity is not a joke. What protein these 
antibodies recognize and its involve-
ment in opioid receptor biology are 
now open questions, as is how sub-
stance P may contribute to morphine 
tolerance. DOR reporters with Myc and 
hemagluttinin tags are expressed in 
LDCVs whereas those with a smaller 
GFP tag are located on the cell surface 
and interact with agonists (Wang et al., 
2008), a further source of potential arti-
fact.
Scherrer et al. argue that expression 
of MOR in TRPV1-expressing nocicep-
tor neurons contributes to analgesia for 
heat pain whereas DOR action in non-
peptidergic sensory neurons results 
in reduction only in mechanical pain. 
These results are intriguing, suggest-
ing that although most nociceptors are 
activated by both heat and mechanical 
stimuli, the input somehow and unex-
pectedly enters the CNS via anatomi-
cally distinct channels. This appears 
difficult to reconcile though with the 
very substantial clinical experience that 
morphine’s analgesic actions are not 
limited to heat pain and the observa-
tion that DOR agonists can very effec-
tively reduce heat pain after peripheral 
inflammation (Codd et al., 2009). Many 
exciting questions remain, not least 
whether DOR agonists will join MOR 
agonists in the pantheon of clinically 
useful opiate analgesics if their pro-
pensity to induce seizures can be fully 
overcome.
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Sprouting blood vessels have tip cells that lead and stalk cells that follow. Benedito et al. 
(2009) now show that competition between endothelial cells for the tip position is regulated by 
glycosylation of Notch receptors and by the opposing actions of the Notch ligands Jagged1 
and Delta-like 4.The vascular system comprises an elabo-
rate network of arteries, capillaries, and 
veins that penetrate all body tissues to 
provide oxygen and nutrients and to 
remove waste. During development, 
new blood vessels form by sprouting 
into avascular zones in a process known 988 Cell 137, June 12, 2009 ©2009 Elsevieras angiogenesis. The primary driver of 
angiogenesis is hypoxia (lack of oxygen). 
Hypoxia accompanies tissue growth and 
triggers the release of angiogenic growth 
factors, the best studied of which is vas-
cular endothelial growth factor (VEGF). 
Endothelial cells line blood vessels and  Inc.normally rest in a quiescent state. In 
response to VEGF, they become activated 
and promote the sprouting of new ves-
sels. The tips of these sprouts are formed 
by specialized endothelial cells called tip 
cells (Figure 1). Tip cells are migratory and 
extend numerous filopodia to sense their 
microenvironment and lead the direction 
of the new sprout. Following behind the 
tip cells, other endothelial cells become 
stalk cells that proliferate and form the 
trunk of the new blood vessel (Siekmann 
et al., 2008). In this issue of Cell, Benedito 
et al. (2009) gain insight into the regulation 
of the balance between tip cell and stalk 
cell specification during angiogenesis.
Why do some endothelial cells become 
tip cells and others stalk cells? Genetic 
studies in mice and zebrafish have estab-
lished that VEGF receptor signaling is 
the primary stimulator of tip cell forma-
tion, whereas Notch signaling provides a 
counteracting inhibitory signal. The trans-
membrane Notch ligand Delta-like 4 (Dll4) 
has a key role in tip cell specification. Its 
expression is induced in tip cells by VEGF, 
and perturbation of Dll4 by genetic loss-
of-function mutation or by pharmacologi-
cal inhibition results in excessive tip cell 
formation and angiogenesis. This indi-
cates that Dll4 normally signals to adja-
cent cells, likely through Notch1, to sup-
press the tip cell phenotype (Phng and 
Gerhardt, 2009). Through this process, 
a single tip cell is selected from among 
several candidate endothelial cells to lead 
a new vessel sprout. Evidence suggests 
that this determination of tip cell ver-
sus stalk cell fate occurs through Notch 
regulation of VEGF receptor expression, 
thus allowing for precise coordination of 
the response to the VEGF signal (Figure 
1). The fine balance between these pro- 
and antiangiogenic pathways enables all 
blood vessels to respond to a localized 
need for new vessel growth but keeps 
such growth under tight control. Benedito 
et al. now show that the Notch ligand Jag-
ged1 (Jag1), which has not been associ-
ated with sprouting angiogenesis, can 
shift this balance to promote new vessel 
growth by antagonizing Dll4-mediated 
Notch signaling.
Benedito et al. use loss-of-function and 
gain-of-function mouse models to investi-
gate the role of Jag1 in retinal angiogenesis. 
As global deletion of Jag1 causes embry-
onic lethality (Xue et al., 1999), the authors 
use a mouse model in which Jag1 is selec-
tively lost in endothelial cells. In these mice, 
retinal angiogenesis is impaired, exhibit-
ing a lower density of blood vessels and 
fewer tip cells. Conversely, overexpression 
of Jag1 in retinal endothelial cells leads 
to increased angiogenesis and more tip 
cells. Thus, in contrast to Dll4, which sup-
presses angiogenesis and tip cell forma-
tion, Jag1 promotes angiogenesis. Does 
Jag1 also act via Notch? Benedito and col-
leagues find that expression of the Notch 
target genes Hey1 and Hes1 increases 
when Jag1 is deleted in endothelial cells. 
This indicates that Notch signaling is 
more active in the absence of Jag1, with 
a corresponding inhibitory effect on ves-
sel growth. If Notch signaling is blocked in 
these mice by a pharmacological inhibitor 
of Notch, angiogenesis and tip cell forma-
tion are induced. This evidence suggests 
that Jag1 negatively regulates Notch activ-
ity. The authors further propose that Jag1 
antagonizes Dll4-mediated Notch activa-
tion. The complementary expression pat-Cell terns of Jag1 and Dll4 in sprouting blood 
vessels support such a hypothesis. Jag1 
is expressed in stalk cells but is absent or 
exhibits reduced expression in tip cells. In 
contrast, Dll4 is strongly expressed in tip 
cells; it is expressed at lower levels in stalk 
cells (Figure 1).
How does Jag1 antagonize Notch acti-
vation? Glycosaminyltransferases of the 
Fringe family, which mediate posttrans-
lational modification of Notch, have been 
shown in other contexts to enhance Notch 
activation by Delta family ligands and 
reduce Notch activation by Jagged fam-
ily ligands (D’Souza et al., 2008). Benedito 
et al. now find that in the vascular system, 
Fringe promotes Notch activation by Dll4 
and reduces Notch activation by Jag1. All 
three mammalian Fringe family members 
are present in blood vessels, with Manic 
Fringe being expressed in tip and stalk 
cells. In cultured mouse endothelial cells, 
both Dll4 and Jag1 can induce expression 
of Notch target genes when Manic Fringe 
is expressed at low basal levels. However, 
if Manic Fringe is overexpressed, only Dll4 
is capable of inducing Notch targets. Simi-
larly, when ligand-bearing cells express-
ing either ligand are mixed with cells 
coexpressing Notch and Manic Fringe, a 
Notch-induced luciferase reporter gene is 
strongly activated by Dll4 but not by Jag1. 
However, if Jag1 and Dll4 are both pres-
ent on the same ligand-bearing cell, or if 
Jag1 and Manic Fringe are both present 
on the same reporter cell, Notch activa-
tion is diminished. This suggests that Jag1 
is capable of antagonizing Dll4-induced 
figure 1. Tip and stalk cell selection in 
sprouting Angiogenesis
Vascular endothelial growth factor (VEGF) pro-
duced by hypoxic cells activates endothelial cells 
to form a new blood vessel sprout. A sprouting 
blood vessel is composed of one tip cell and many 
stalk cells. VEGF induces expression of Delta-like 
4 (Dll4) in the tip cell, which signals to stalk cells to 
activate Notch downstream targets and to reduce 
VEGF receptor expression levels, thereby sup-
pressing tip cell fate. In the stalk cell, the glyco-
syltransferase Fringe modifies Notch receptors to 
enhance Notch signaling induced by Dll4 from the 
tip cell, further reducing stalk cell VEGF receptor 
(VEGFR) levels and perhaps inducing quiescence. 
However, Jagged-1 (Jag1) in the stalk cell can an-
tagonize Dll4-Notch signaling to maintain an ac-
tivated stalk cell phenotype that is responsive to 
VEGF, thereby promoting angiogenesis. Stalk cells 
also express low levels of Dll4. Fringe could allow 
for Jag1 to inhibit possible Dll4-mediated signaling 
between stalk cells or from stalk cells to the tip 
cell. In tip cells lacking Fringe, Jag1 might promote 
angiogenesis by signaling directly to Notch to in-
duce VEGFR3 expression.137, June 12, 2009 ©2009 Elsevier Inc. 989
Notch activation. These observations 
in cultured cells are relevant in vivo, as 
residual levels of Dll4 that could poten-
tially suppress angiogenesis are present in 
stalk cells. By antagonizing these signals, 
Jag1 can promote stalk cell activation and 
maintain the VEGF response. Supporting 
evidence for Fringe-mediated regulation 
of angiogenesis also comes from genetic 
deletion of another Fringe family member, 
Lunatic Fringe, in mice. Loss of Lunatic 
Fringe results in enhanced retinal angio-
genesis and increased tip cell numbers, 
indicating reduced Notch activation.
In addition to antagonizing Dll4-medi-
ated activation of Notch signaling, Jag1 
could also promote angiogenesis by sig-
naling directly to tip cells to regulate the 
expression of VEGF receptor 3 (VEGFR3). 
VEGFR3 has a crucial role in mediating 
the growth of lymphatic vessels, but it 
is also expressed in endothelial tip cells 
where it promotes angiogenesis. Indeed, 
a recent study has shown that disrup-
tion of VEGFR3 function in endothelial tip 
cells using monoclonal antibodies blocks 
vascular sprouting (Tammela et al., 2008). 
Benedito et al. show that VEGFR3 expres-
sion in tip cells is decreased when Jag1 is 
deleted, providing a mechanistic explana-
tion for why these tip cells could have an 
impaired sprouting response. Thus, one 990 Cell 137, June 12, 2009 ©2009 Elsevier 
MicroRNAs (miRNAs) play fundamental 
roles in the regulation of gene expression 
by pairing via partial Watson Crick inter-
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The loss of expression of particu
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re-establishing the expression ofcould envision that, just as Dll4-Notch 
signaling downregulates expression of 
the VEGF receptor in stalk cells to inhibit 
vessel growth, Jag1-Notch signaling could 
upregulate VEGFR3 expression in tip cells 
to promote vessel growth.
A key question arising from this work 
is how Jag1 and Fringe family members 
are themselves regulated in endothelial 
cells. Jag1 expression can be induced 
in vitro by inflammatory factors such as 
tumor necrosis factor α, which could pro-
vide a means for integrating signals from 
the local microenvironment to promote 
new vessel growth (Sainson et al., 2008). 
Evidence from the study of Benedito et 
al. suggests that Fringe is not expressed 
uniformly in sprouting vessels but is found 
in subsets of stalk and tip cells. Given the 
crucial roles that Fringe members could 
play in regulating angiogenesis, under-
standing the upstream factors that control 
their expression will be essential to fur-
ther unraveling their function. Lastly, Jag1 
clearly plays additional roles during angio-
genesis beyond those in tip and stalk cell 
selection, and it also functions in tissues 
other than blood vessels (Hofmann and 
Iruela-Arispe, 2007). In humans, for exam-
ple, haploinsufficiency of Jag1 causes 
Alagille Syndrome, which is character-
ized by abnormalities in the cardiovascu-Inc.
within the 3′ untranslated regions (UTRs) 
of targeted transcripts (Bartel and Chen, 
2004; Bartel, 2009). There are now 
numerous examples linking dysregu-
 MicroRnA The
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 an miRNA using a viral vector.lar system, liver, eye, and skeleton (Grid-
ley, 2003). The ability to selectively delete 
Jag1 in different tissues and at different 
developmental stages in model organisms 
should allow more detailed investigation of 
the pathogenesis of this disease.
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